Viron logo — company profile

Viron

Founded 1990 Series B Total: $75.00M Health Care

General Information

Company Name Viron
Founded Year 1990
Industries Health Care
Funding Stage Series B
Social

Get notified when Viron moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Viron

Viron is a biopharmaceutical company that has been making groundbreaking strides since its establishment in 1990. The company's focus lies in discovering and developing high-value therapies for critical protein and lipid targets related to a range of health issues, including cancer, Alzheimer's, diabetes, neurological, digestive, and immune disorders. This commitment to advancing medicine is driven by a fusion of cutting-edge technologies, such as genomics, gene editing, stem cell biology, patient-derived organoids, cryo-electron microscopy, synthetic biology, small molecule screening, and AI-powered image analysis through high-throughput screening. These innovations have significantly reshaped the landscape of drug discovery. Viron's success and potential have attracted significant attention from investors, culminating in a $50.00M Series B investment received on 08 December 2021. This round of funding brought in support from a diverse group of prominent financial backers, including B Capital Group, Xeraya Capital, BIVF, City Hill Ventures, Delos Capital, Korean Investment Partners, Lumira Ventures, Madison Partners, LYZZ CAPITAL, and Private Ventures Group ("PVG"). This strong financial backing serves as a testament to the confidence these reputable investors have in Viron's vision and capabilities in revolutionizing healthcare through innovative drug development.

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• 10
Investor Investor Investor Investor Investor Investor Investor Investor Investor
•••• ••••
08 Dec 2021
Series A •••••• - 06 Jun 2019

Viron Alternatives & Competitors

Viron vs
Kojin Therapeutics
Kojin Therapeutics United States

Developing transformative medicines based on a groundbreaking approach to ferroptosis and cell state...

Series A
7 employees
Biopharma, Biotechnology
Viron vs

The Integrated Fragment Discovery Engine

44 employees
Biotechnology, Health Care
Viron vs

Advancing cellular biology research with innovative biosensor technology for precise, high-throughpu...

Series Unknown
2-10 employees
Biotechnology, Life Sciences

FAQ About Viron

Viron is a biopharmaceutical company focused on breakthrough discovery and advanced technologies to identify and develop high-value therapies for critical protein and lipid targets in cancer, Alzheimer's, diabetes, neurological, digestive, and immune disorders. Advances in genomics, gene editing, st...
Viron was founded in 1990.
Viron operates in the following industries: Health Care.
Viron has completed 2 funding rounds, raising a total of $75.00M. The latest funding stage is Series B.
Top alternatives and competitors to Viron include Kojin Therapeutics, ZoBio, Sharp Edge Labs, Adeptrix Corporation, Domainex. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Viron and Kojin Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Viron and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy